Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $62.01 million for the quarter.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter in the prior year, the business posted ($1.21) EPS. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Keros Therapeutics Stock Down 5.5 %

KROS opened at $13.76 on Wednesday. The stock has a market cap of $558.81 million, a PE ratio of -2.64 and a beta of 1.32. The business has a 50 day moving average of $12.05 and a 200-day moving average of $25.42. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KROS. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Wells Fargo & Company reduced their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Wedbush reaffirmed a “neutral” rating and set a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Finally, Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.